Semma Therapeutics Announces Publication Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes

Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the journal Nature published data demonstrating improvements in the production of beta cells (cells that produce insulin) from stem cells. Led by Harvard University researchers in collaboration with scientists from Semma, the study characterized the types of cells produced by the applicable cell differentiation methods,...

Pushing early beta-cell proliferation can halt autoimmune attack in type 1 diabetes model – Joslin

Researchers at Joslin have found that increasing the proliferation and turnover of beta cells before signs of type 1 diabetes could halt the development of the disease. In animal models, researchers in the lab of Rohit N. Kulkarni MD PhD, HMS Professor of Medicine and Co-Section Head of Islet and Regenerative Biology in the Joslin Diabetes Center, pushed the growth of beta cells...